How were Aduro Biotech's earnings last quarter?

Aduro Biotech, Inc. (NASDAQ:ADRO) posted its earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to analysts' expectations of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%.

What other stocks do shareholders of Aduro Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS) , Exact Sciences (EXAS) , Flexion Therapeutics (FLXN) , Paratek Pharmaceuticals (PRTK) , Nabriva Therapeutics (NBRV) , Amarin (AMRN) , Anavex Life Sciences (AVXL) , Micron Technology (MU) , VBI Vaccines (VBIV) and PTC Therapeutics (PTCT) .

When did Aduro Biotech IPO?

Aduro Biotech (ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

NASDAQ:ADRO

Aduro Biotech (ADRO) Stock Price, News & Analysis

→ The #1 Crypto for 2024 (From InvestorPlace) (Ad)

Free ADRO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $2.28
▼
$14.60
52-Week Range: N/A

Volume: 171,500 shs
Average Volume: 162,237 shs
Market Capitalization: $236.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Aduro Biotech alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Aduro Biotech Stock (NASDAQ:ADRO)

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

ADRO Stock News Headlines

February 24, 2024 | morningstar.com

Aduro Clean Technologies Inc Ordinary Shares

January 3, 2024 | morningstar.com

PT Adaro Energy Indonesia Tbk

April 18, 2024 | Crypto Swap Profits (Ad)

He Is Giving Away Bitcoin

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

December 2, 2023 | morningstar.com

PT Adaro Energy Indonesia Tbk ADRO

November 16, 2023 | benzinga.com

Legend Biotech Stock (NASDAQ:LEGN), Analyst Ratings, Price Targets, Predictions

November 10, 2023 | seekingalpha.com

Bret Jensen

November 6, 2023 | reuters.com

Concord Biotech Ltd

June 26, 2023 | thestreet.com

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study

April 18, 2024 | Crypto Swap Profits (Ad)

He Is Giving Away Bitcoin

March 18, 2023 | finance.yahoo.com

French biotech Sensorion does not expect any impact to its liquidity from SVB's closure

March 15, 2023 | reuters.com

SVB shock could have chilling effect on British biotech sector

March 15, 2023 | cnbc.com

SVB fallout: The impacts on the biotech sector

December 17, 2022 | thestreet.com

Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles in Value On IPO Debut

November 30, 2022 | finance.yahoo.com

Aduro Selected for Shell GameChanger Program

October 29, 2022 | barrons.com

Merck’s CFO Says Biotech Deals are Getting Done

September 28, 2022 | finance.yahoo.com

PT Adaro Energy Indonesia Tbk (ADRO.JK)

July 31, 2021 | barrons.com

Adaro Energy

See More Headlines

Receive ADRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aduro Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/04/2020
Today: 4/18/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ADRO
CUSIP: N/A
CIK: 1435049
Web: www.aduro.com
Phone: (206) 485-7051
Fax: N/A
Employees: 152
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($5.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-82,370,000.00
Net Margins: -230.92%
Pretax Margin: N/A
Return on Equity: -101.73%
Return on Assets: -22.35%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.91
Quick Ratio: 8.91

Sales & Book Value

Annual Sales: $17.26 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.07 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 16,212,000
Free Float: N/A
Market Cap: $236.61 million
Optionable: Optionable
Beta: 0.40

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Eric L. Dobmeier
Chairman, President & Chief Executive Officer
Alan Glicklich
Chief Medical Officer
Kirk D. Schumacher
Senior Vice President & General Counsel
Tom Frohlich
Chief Business Officer
Noopur Liffick
VP-Investor Relations & Corporate Communications

Key Competitors

View All Competitors

ADRO Stock Analysis - Frequently Asked Questions

How were Aduro Biotech's earnings last quarter?: Aduro Biotech, Inc. (NASDAQ:ADRO) posted its earnings results on Monday, May, 4th. The biotechnology company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biotechnology company earned $13.95 million during the quarter, compared to analysts' expectations of $8.81 million. Aduro Biotech had a negative net margin of 230.92% and a negative trailing twelve-month return on equity of 101.73%.
What other stocks do shareholders of Aduro Biotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro Biotech investors own include Regulus Therapeutics (RGLS), Exact Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Nabriva Therapeutics (NBRV), Amarin (AMRN), Anavex Life Sciences (AVXL), Micron Technology (MU), VBI Vaccines (VBIV) and PTC Therapeutics (PTCT).
When did Aduro Biotech IPO?: Aduro Biotech (ADRO) raised $119 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

This page (NASDAQ:ADRO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aduro Biotech (ADRO) Stock Price, News & Analysis

About Aduro Biotech Stock (NASDAQ:ADRO)

ADRO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ADRO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info